An open, single dose, antitumor effect study of 2-hydroxyflutamide as a controlled release product (Liproca Depot), injected into the prostate in patients with localized prostate cancer.
Phase of Trial: Phase II
Latest Information Update: 15 Mar 2016
At a glance
- Drugs Hydroxyflutamide (Primary)
- Indications Prostate cancer
- Focus Pharmacodynamics
- Sponsors LIDDS
- 07 Jun 2017 Biomarkers information updated
- 10 Mar 2016 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 13 Jan 2015 Planned End Date changed from 21 Feb 2012 to 1 May 2016, according to ClinicalTrials.gov record.